Hypopharyngeal carcinoma (HC) is one of the most malignant tumors in the upper aerodigestive tract. Currently, there are no effective treatments for HC. Gold nanoparticles (AuNPs) are a promising tool that can be used for plasmonic photothermal therapy (PPTT), which refers to the use of electromagnetic radiation, most often in near infrared (NIR) region, for the treatment of various medical conditions including cancer. AuNPs have been proved to be a promising tool for NIR spectroscopy-mediated photothermal therapies. In this study, we chemically conjugated AuNPs with a monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR), a cellsurface receptor that is overexpressed in many cancers. We then assessed the effect of NIR photothermal treatment with the EGFRmAb-AuNPs in FaDu HC cells. Our data showed that nanoparticle conjugation with the EGFRmAb improved the specific targeting towards FaDu cells and reduced cytotoxicity towards normal (293 T) cells which do not overexpress the EGFR. A significant amount of our EGFRmAb-conjugated AuNPs could enter the nucleus. Moreover, the expression levels of double strand DNA break repair proteins, including p-ATR, p-CHK1, and p-CHK2 were increased following AuNPs treatment, indicating the presence of DNA damage. These findings suggest that the AuNPs can potentially disrupt genome integrity and induce apoptosis. In addition, EGFRmAbAuNPs+NIR could induce FaDu cell apoptosis, accompanied by the inhibition of the PI3K/AKT/ mTOR pathway and stimulation of DNA damage response. Based on these data, PPTT using the EGFRmAb-AuNPs could be a new promising treatment for HC.
Introduction
Hypopharyngeal carcinoma (HC) belongs to the category of head and neck squamous cell carcinomas (HNSCCs). HNSCC is the sixth most prevalent cancer worldwide, and is responsible for 90% of the cancers that arise in the mucosal surfaces of the head and neck [1] . Most HCs develop in the piriform fossa, and are one of the most malignant tumors found in the upper aerodigestive tract; unfortunately, the incidence rate continues to rise year-by-year [2] . Because patients are usually asymptomatic, it is mostly diagnosed at the middle-late stage. The 5-year survival rate for HNSCC is only around 40%, and has not been improved over the last two decades [3] . It is therefore urgent for clinicians and scientists to develop new treatments to eradicate HC, while preserving hypopharyngeal functions, reducing recurrence, and improving survival rate.
Gold nanoparticles (AuNPs) are a promising tool that can be used for plasmonic photothermal therapy (PPTT), which refers to the use of electromagnetic radiation, most often in near infrared (NIR) region, for the treatment of various medical conditions, including cancer [4, 5] . Radiation in the NIR range can penetrate deeply into living tissues, with little effect of the fluorescence on the tissue. The AuNPs can effectively absorb and convert the light energy in the NIR range into a large amount of heat, an effect caused by surface plasmon resonance (SPR). The resulting heat can selectively induce apoptosis in tumor cells without damaging the surrounding normal tissues. Gold nanorods are one type of AuNPs that have two characteristic SPR absorbance peaks. The transverse surface plasmon resonance (TSPR) peak is around 520 nm, and is characteristic of all AuNPs, whereas the long surface plasmon resonance (LSPR) peak is a variable of the gold nanorod particle's aspect ratio, and thus can be manually tuned [4] . When the aspect ratio is 3.9, the LSPR is found at 800 nm, right at the middle of the NIR spectrum. Moreover, AuNPs can be conjugated with tumortargeting antibodies to achieve higher selectivity and efficacy [6] [7] [8] .
The epidermal growth factor receptor (EGFR) is a cell-surface receptor that binds epidermal growth factors [9] . Mutations that affect EGFR expression or activity contribute to the proliferation and invasion of various cancer cells. It has been shown that the EGFR is overexpressed in many types of carcinoma, such as nonsmall cell lung cancer, metastatic colorectal cancer, and pancreatic ductal adenocarcinoma [10] [11] [12] [13] . Moreover, the EGFR is overexpressed in up to 90% of HNSCCs, as compared with that in normal mucosa [14] . Recent studies have shown that anti-EGFR monoclonal antibody (EGFRmAb) conjugated to AuNPs (EGFRmAbAuNPs) can induce the apoptosis of HSC and HOC malignant cells [15] as well as Hep-2 laryngeal cancer cells [16] . However, the effects of EGFRmAb-AuNPs in HC cells and the mechanism of their antitumor activity are still unclear.
In the present study, we chemically conjugated AuNPs (specifically gold nanorods) with EGFRmAb and evaluated photothermal treatment using the EGFRmAb-AuNPs in FaDu HC cells. Our data demonstrated that conjugation with the EGFRmAb increased the entry of AuNPs into FaDu HC cells. When treated with NIR radiation, EGFRmAb-AuNPs effectively induced FaDu cell apoptosis. We also found that the EGFRmAb-AuNPs induced cell apoptosis that was associated with inhibition of the PI3K/AKT/mTOR pathway and also stimulated the DNA damage response. Our results demonstrate that these conjugated AuNPs can be used for PPTT in HC cells.
Materials and Methods

Cell lines and cell culture
The FaDu HC cell line was purchased from the Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China). The human kidney epithelial 293 T cell line was a gift from Kunming Institute of Zoology, Chinese Academy of Sciences (Kunming, China). Both cell lines were cultured in minimum essential medium (MEM; HyClone, Logan, USA) containing 10% fetal bovine serum (FBS; Life technologies, Camarillo, USA) at 37°C with a humidified atmosphere containing 5% CO 2 .
Preparation of AuNPs and conjugation with EGFRmAb
AuNPs were synthesized by the Kunming Institute of Precious Metals (Kunming, China) using a seeded growth technique, as previously described [17, 18] . To prepare the EGFRmAb-AuNPs conjugates, the EGFRmAb (Sigma-Aldrich, St Louis, USA) was dissolved in HEPES buffer (HEPES 20 mM, pH 7.4) and used to create a series of EGFRmAb solutions with different concentrations. AuNPs were also suspended in HEPES buffer to produce a solution with an optical density of 0.8 at 800 nm. Each 0.5 ml of the EGFRmAb solution was mixed with 10 ml of AuNPs solution and agitated for 30 min. Polyethylene glycol (Sigma-Aldrich) was used to conjugate the EGFRmAb to the AuNPs. The absorption spectra of the AuNPs and EGFRmAb-AuNPs were determined using an ultraviolet-visible (UV-vis)-NIR spectrometer (Lambda 900; PerkinElmer Inc., Hopkinton, USA). The optimal EGFRmAb concentration was chosen as being the one that gave the maximum absorption for the EGFRmAb-AuNPs. The selected EGFRmAb-AuNPs solution was centrifuged for 10 min at 23,200 g and the pelleted EGFRmAbAuNPs conjugate was dissolved in phosphate-buffered saline (PBS, pH 7.4). The solutions were stored at 4°C before use. The synthetic EGFRmAb-AuNPs (0.1 nM) were examined under JEM 1010 transmission electron microscope (TEM; JEOL Ltd, Tokyo, Japan) to determine the mean values for the long and transverse diameters of the nanorod particles. Spectroscopically, the AuNPs have a TSPR at 520 nm and an LSPR at 800 nm consistent with their rod-like shape.
AuNPs cytotoxicity test
To determine the cytotoxic effect of the AuNPs on cells, 15, 25, or 35 μl of the AuNPs solution was added to either FaDu cells or 293 T cells (1.4 × 10 5 cells/ml), respectively, in a total volume of 100 μl.
The cells were then incubated at 25°C for 1 h. A diode laser K81S09F (BWT Beijing Ltd, Beijing, China) was used to conduct the laser irradiation analysis at 808 nm. The red laser, at 808 nm, was focused on a 1-mm diameter spot on the sample for a total of 6 min. Cytotoxicity was quantitated by measuring LDH release using an LDH kit from Roche (St Louis, USA) following the manufacturer's recommended protocol. Each sample was measured in triplicate. Cell proliferation rates were measured using an XTT kit (Roche) in cells treated in an identical manner as described above. The temperature of cell media was measured every minute for 6 min following NIR irradiation.
Apoptosis assay
The 
Western blot analysis
Whole cell lysates were prepared in RIPA buffer supplemented with protease inhibitors (Beyotime Biotechnology Inc., Haimen, China). Protein concentrations were measured using a BCA assay (Beyotime Biotechnology Inc.) according to the manufacturer's recommended protocol. Equal amounts of protein (70 μg) were loaded onto 4% SDS-PAGE to separate proteins and then transferred to PVDF membranes. The resulting membranes were blocked with 5% bovine serum albumin (BSA; Beijing Solarbio Science and Technology Co., Ltd, Beijing, China) at room temperature for 1 h. Following this, the membranes were individually probed with primary antibodies (Abcam, Shanghai, China) recognizing p-AKT-T308, p-AKT-S473, p-ATR, p-CHK1, p-CHK2, PI3K, p-PDK1, p-PTEN, GSK-3β, total AKT, and β-actin, respectively. Subsequently, the membranes were incubated with the appropriate secondary antibody (Abcam) for 2 h at room temperature. The membranes visualized using an ECL kit (Millipore, Bierlika, USA) and imaged with a Bio-Rad GelDock system (Bio-Rad, Hercules, USA).
Q-PCR
Cells were lysed with TRIZOL lysis buffer (Life Technologies, Carlsbad, USA) and the total RNA was extracted with chloroform (Sigma, St Louis, USA). Then RNA was precipitated with isopropanol (Aladdin, Shanghai, China). After that, it was dissovled in 20 μl RNA-free water (Fermentas, Ontario, Canada). The concentration of RNA was measured with NanoDrop 2000 (Thermo, Waltham, USA). Reverse transcription using First Strand cDNA Synthesis Kit (Fermentas, Ontario, Canada) was performed with 1 μg total RNA. The first strand cDNA could be obtained, and it was amplified with a SYBR Green Mix Kit (Bio-Rad). Q-PCR reaction was taken place in ABI Step One Plus (ABI, Carlsbad, USA). PCR cycles were as follows: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for 30 s. Target quantity (2
−ΔΔCT
) was acquired via normalization to GAPDH and correlated with a calibrator (average of the control specimens). The primers used for Q-PCR are listed in Table 1 .
Statistical analysis
SPSS17
.0 was used to analyze the data and perform a nonparametric Mann-Whitney U test. The analysis of variance for randomized blocks was conducted, and P < 0.05 was regarded as statistically significant.
Results
Construction of EGFRmAb-AuNPs
The AuNPs in this study had dimensions of 50 × 12 nm and an aspect ratio of 3.9, which were confirmed to be nanorods. TEM images showed that samples of the AuNPs were homogeneous and well dispersed in solution (Fig. 1A) . Spectroscopically, the AuNPs have a TSPR at 520 nm and an LSPR at 800 nm (Fig. 1B) consistent with their rod-like shape. Polyethylene glycol was used to conjugate the EGFRmAb to the AuNPs. The LSPR of the resulting EGFRmAb-AuNPs was slightly red shifted to~810 nm, compared with the unconjugated AuNPs (Fig. 1B) .
EGFRmAb conjugation improves the specificity of the AuNPs
We tested the effect of EGFRmAb-AuNPs on FaDu cells, using 293 T cells as a control. Consistent with a previous report [19] , the EGFR was found to be overexpressed in FaDu cells but not in 293 T cells (data not shown). Confocal microscopy showed that EGFRmAb conjugation to the AuNPs improved their transport into FaDu cells. In FaDu cells, the cellular uptake of the EGFRmAb-AuNPs was increased significantly compared with AuNPs alone (Fig. 1C,D) . In contrast, in 293 T cells, the level of cellular uptake of the EGFRmAb-AuNPs was significantly reduced compared with AuNPs alone (Fig. 1E,F) . The AuNPs were found to be enriched mainly in the cytoplasm, while a small number were also found in the nucleus. Our data therefore demonstrated that conjugation of AuNPs with the EGFRmAb inhibits uptake into 293 T cells, but improves their cell specific uptake into FaDu cells overexpressing the EGFR.
Cytotoxicity of EGFRmAb-AuNPs+NIR in FaDu and 293 T cells
We next tested the cytotoxicity of EGFRmAb-AuNPs by measuring the release of LDH using an LDH activity assay. AuNPs only treatment was cytotoxic to both FaDu cells and 293 T cells compared with blank controls (Fig. 2A,B) , presumably because of the oxidative stress induced by the AuNPs [20] . Treatment with the EGFRmAb alone also increased LDH release in FaDu cells, suggesting that the antibody alone is cytotoxic to FaDu cells. Interestingly, conjugation of AuNPs with the EGFRmAb significantly reduced 
cytotoxicity compared with EGFRmAb alone in both FaDu and 293 T cells ( Fig. 2A,B) . In contrast, treatment of cells with NIR radiation induced the cytotoxicity of EGFRmAb-AuNPs group in FaDu cells compared with the same treatment group in 293 T cells. A comparison of cytotoxicity in these two cell lines using three different concentrations of AuNPs and different concentrations of EGFRmAb-AuNPs showed that there were statistically different levels of cytotoxicity in both cell lines. Importantly, EGFRmAb-AuNPs+NIR enhanced the cytotoxicity towards maglinant tumor cells compared with only AuNPs group among three different concentrations, however, there is no obverse difference between EGFRmAb-AuNPs+NIR and AuNPs+NIR group ( Fig. 2A) . Another important thing we must notice was that the cytotoxicity was significantly decreased in EGFRmAb-AuNPs+NIR group compared with AuNPs+NIR group in 293 T cells among three different concentrations (Fig. 2B) . In contrast, at lower concentration of gold nanorods (15% and 25%), cell cytotoxicity of the conjugation with NIR was much lower than 293 T cells treated with only AuNPs; and at high concentration of gold nanorods (35%), EGFRmAb-AuNPs+NIR group showed high cell cytotoxicity in both cell lines. In the presence of NIR radiation, EGFRmAb-AuNPs at the same concentration were more toxic to FaDu cells than to 293 T cells ( Fig. 2A,B , P < 0.01). In 293 T cells, the cytotoxicity of the AuNPs coated with the EGFRmAb was significantly reduced, whereas the uncoated AuNPs showed higher cytotoxicity. Data are presented as the mean ± SD from three independent experiments. *P < 0.05, **P < 0.01; # P < 0.05, ## P < 0.01. EGFR-Au, EGFRmAb-AuNPs; Au, AuNPs. The cell proliferation rate was also measured using the XTT method. The EGFRmAb-AuNPs with NIR (35%) significantly reduced the cell proliferation rate of FaDu cells in the presence of NIR compared with the 15% and 25% EGFRmAb-AuNPs with NIR group ( Table 2) . As controls, NIR treatment alone displayed little effect on cell proliferation, whereas EGFRmAb treatment alone moderately reduced the cell proliferation rate ( Table 3) . PPTT relies on NIR-induced heat release to kill cancer cells. We thus assessed temperature changes in the cell culture media following NIR treatment. NIR raised the temperature of the cell media in the presence of AuNPs (Fig. 3A,B) . The NIR-induced temperature elevation was positively correlated with the NIR treatment time, as well as with the EGFRmAb-AuNPs concentration. Under the same conditions, conjugation with the EGFRmAb increased the temperature effect in the presence of NIR in both FaDu and 293 T cells.
EGFRmAb-AuNPs+NIR induces FaDu cell apoptosis
We further investigated whether EGFRmAb-AuNPs+NIR induces cell death via apoptosis. We assessed this in FaDu cells using FITClabeled Annexin V staining/PI staining. Annexin V can specifically bind to phosphatidylserine (PS) in a calcium-dependent manner. In healthy cells, PS is predominantly located on the inner leaflet of the plasma membrane (i.e. on the cytosolic side) and is not accessible to Annexin V. Following the induction of apoptosis, PS translocates to the outer leaflet of the plasma membrane where it is detectable by the FITC-labeled Annexin V (FITC+). Necrotic cells have damaged membranes and thus can also be stained by Annexin V (FITC+). For apoptotic or healthy cells, the plasma membrane excludes the dye PI (PI − ), whereas necrotic cells can be stained with PI (PI + ).
Using flow cytometry, we showed that most FaDu cells treated with EGFRmAb-AuNPs in the presence of NIR were FITC + /PI − , in comparison, FaDu cells in the blank control were mainly FITC − /PI − (Fig. 4A) . Under fluorescence microscopy, FaDu cells treated with EGFRmAb-AuNPs in the presence of NIR radiation showed strong evidence of FITC fluorescence (green), but little PI fluorescence (red) (Fig. 4B) . These results clearly indicated that in the presence of NIR radiation, the EGFRmAb-AuNPs conjugate effectively induces FaDu cell death through apoptosis. EGFRmAb-AuNPs+NIR-induced apoptosis was further verified using an ELISA method. The mouse mAb used in this ELISA assay can bind to both DNA and histone with its two ends. This ELISA assay can thus be used to quantitatively identify individual or oligo nucleosomes that are generated during apoptosis. Cells treated with EGFRmAb-AuNPs+NIR displayed a much higher ELISA signal in this assay compared with cells in the blank control (Fig. 4C) . This indicated that the cells were apoptotic again.
We also examined TUNEL-FITC staining of FaDu cells treated with EGFRmAb-AuNPs in the presence of NIR radiation. Apoptotic cells can be stained by TUNEL-FITC because of the fact that they contain fragmented chromosomal DNA. All cells can be stained with DAPI, because of its membrane permeability. Confocal microscopy showed that TUNEL-FITC staining overlapped with both DAPI staining and the AuNPs-derived fluorescence, indicating that AuNPs can specifically enter the cell and induce apoptosis (Fig. 4D) . The blank control treated cells could only be stained with DAPI.
Effect of EGFRmAb-AuNPs+NIR on the expression of apoptotic proteins
To explore the effect of EGFRmAb-AuNPs+NIR on the expression of apoptotic proteins, western blot analysis was used to assess the expression levels of Bcl-2 and Bax following treatment of FaDu cells with EGFRmAb-AuNPs+NIR. It was found that Bcl-2 expression in FaDu cells was reduced by EGFRmAb-AuNPs in the presence of NIR, whereas Bax expression was increased (Fig. 5A-C) . The level of caspase 3 was increased after treatment of FaDu cells with EGFRmAb-AuNPs in the presence of NIR radiation (Fig. 5A,D) . In addition, caspase 9 expression was elevated compare with the AuNP group when FaDu cells were treated with EGFRmAb-AuNPs, and over half of the caspase 9 was cleaved to the active form (Fig. 5A,E) . These results indicated that EGFRmAbAuNPs treatment affects the expression of apoptotic proteins. EGFRmAb-AuNPs+NIR induces apoptosis via the PI3K/AKT/mTOR and DNA damage response pathways
Because the activated EGFR triggers several downstream signaling pathways, including the PI3K/AKT/mTOR pathway [9] , we therefore explored whether EGFRmAb-AuNPs+NIR-induced apoptosis via the PI3K/AKT/mTOR pathway. During activation, AKT can be phosphorylated at Thr308 and Ser473. The activated AKT can then phosphorylate downstream Bax, caspase 3, and caspase 9, and eventually inhibit apoptosis. Although the mRNA level of AKT in FaDu cells was increased with EGFRmAb-AuNPs+NIR treatment (Fig. 6A) , the phosphorylations of Thr308 and Ser473 of EGFRmAb-AuNPs+NIR were largely reduced compared with AuNPs, as shown by western blot analysis (Fig. 7) . p-PDK1 is responsible for phosphorylation of AKT at Thr308. Interestingly, following EGFRmAb-AuNPs+NIR treatment, the mRNA level of PDK1 was increased, and the protein level was increased compared with AuNPs group (Figs. 6B and 7) . In addition, a downstream factor in the PI3K/AKT/mTOR pathway, GSK-3β, showed an increase in its mRNA level, but the level of GSK-3β was largely reduced compared between EGFRmAb-AuNPs+NIR and AuNPs group (Figs. 6C and 7) . These data further confirmed that the PI3K/AKT/mTOR pathway was downregulated following treatment of FaDu cells with EGFRmAbAuNPs+NIR. Phosphorylated PTEN is a tumor suppressor that negatively regulates the PI3K/AKT/mTOR pathway [21] . Both the PTEN mRNA expression level and level of phosphorylated PTEN were elevated following EGFRmAb-AuNPs+NIR treatment (Figs. 6D and 7) . These data strongly suggested that the PI3K/AKT/mTOR pathway is downregulated following EGFRmAb-AuNPs+NIR treatment.
We also assessed the expression levels of DNA damage response factors such as ATM, ATR, and BRCA1 that promote the DNA damage response or apoptosis [22] . In FaDu cells treated with EGFRmAb-AuNPs+NIR, ATM and BRCA1 mRNA levels were drastically stimulated, indicating a severe loss of genomic integrity (Fig. 6E,G) . Compared with AuNPs group, ATR mRNA level had a slight decline (Fig. 6F) , but the protein level of phosphorylated ATR was increased significantly (Fig. 7) in EGFRmAb-AuNPs+NIR treatment. In addition, CHK1 and CHK2 were activated by phosphorylation, as indicated by western blot analysis in EGFRmAb-AuNPs+NIR group (Fig. 7) . These findings suggested that EGFRmAb-AuNPs+NIR-induced apoptosis via the PI3K/AKT/mTOR and DNA damage response pathways.
Discussion
HC patients have a low survival rate owing to difficulties in diagnosis and surgery. Hyperthermia therapy has been successfully applied to treat several types of cancer. Tumor tissues are more susceptible to high temperature because of the vascular disorganization that is often found within the tumor. Yet, various adverse effects limit the general application of hyperthermia therapy. In this regard, the development of nanomaterials has greatly advanced the controllability of hyperthermia. AuNPs, which have an SPR effect following exposure to NIR radiation, have been shown to be effective for PPTT. However, AuNPs have a poor specificity for tumor cells and a high cytotoxicity in normal tissues, as shown by our data. In this report, we conjugated rod-shaped AuNPs with an EGFRmAb and tested the effect of the EGFRmAb-AuNPs conjugate in the FaDu HC cell line. Our data showed that conjugation with the EGFRmAb significantly reduced the cytotoxicity of the conjugated AuNPs towards normal tissue. The NIR-induced temperature elevation was positively correlated with the NIR treatment time, as well as with the EGFRmAb-AuNPs concentration. Although in 15% EGFRmAbAuNPs+NIR group, the temperature was a little higher in 293 T cells than in FaDu cell line, under the same conditions, conjugation with the EGFRmAb increased the temperature effect in the presence of NIR in both FaDu and 293 T cells. Moreover, the EGFRmAb conjugation promoted the uptake of the conjugated AuNPs into FaDu cells. In the presence of NIR radiation, the EGFRmAb-AuNPs effectively induced FaDu cell apoptosis. Our data proved that the conjugation with an EGFRmAb improved both cell selectivity and efficacy of AuNPs in FaDu cells. Therefore, PPTT using EGFRmAb-AuNPs+NIR could be a new promising treatment for HC. It is well known that apoptosis is a normal process that occurs during the cell life cycle and is associated with few medical conditions, whereas necrosis causes inflammation and tissue death [23] . In this study, we found that FaDu cells treated with EGFRmAbAuNPs+NIR showed the characteristics of apoptosis, being well stained by Annexin V or TUNEL but not by PI. It is known that caspase 9 is an initiator caspase [24] . Pro-caspase 9 has a molecular weight of 46 kDa, and during apoptosis it is activated by protease cleavage to produce a 35-kDa fragment. This active caspase 9 can then cleave the downstream caspase 3 and caspase 7, and initiate the apoptosis cascade. Caspase 3 is considered to be an effector caspase during apoptosis [24] . Our data showed that the expression and activity of the caspase proteins caspase 9 and caspase 3 were increased in FaDu cells treated with EGFRmAb-AuNPs+NIR. The Bcl-2 family proteins are regulators of apoptosis. Bcl-2, Bcl-xL, and Bcl-xY are apoptosis inhibitors, whereas Bax, Bad, Bix, and Bcl-xS are apoptosis activators [25] . Our data demonstrated that the expression of apoptosis inhibitor Bcl-2 was decreased, whereas expression of the apoptosis promotor Bax was increased, in FaDu cells treated with EGFRmAb-AuNPs+NIR. All the evidence indicated that EGFRmAb-AuNPs+NIR induces FaDu cell apoptosis.
In addition, we explored the molecular mechanism of EGFRmAbAuNPs+NIR-induced apoptosis. The EGFR and its downstream signaling pathways are activated in many malignant cancers. It has been shown that the activated EGFR triggers the PI3K/AKT/mTOR pathway [9] . The activated PI3K/AKT/mTOR pathway can inhibit apoptosis and lead to uncontrolled cell growth. During activation, AKT can be phosphorylated at both Thr308 and Ser473. The activated AKT can then phosphorylate downstream Bax, caspase 3, and caspase 9 and eventually inhibit apoptosis [26] . In this study, the phosphorylation of AKT at both Thr308 and Ser473 was found to be significantly reduced by EGFRmAb-AuNPs+NIR treatment. Further, the level of p-PDK1, which is responsible for phosphorylation of AKT at Thr308, was also decreased in FaDu cells following EGFRmAbAuNPs+NIR treatment. Consistent with this, the phosphorylation level of GSK-3β, a downstream target of the PI3K/AKT/mTOR pathway [27] , was largely decreased. Furthermore, the level of p-PTEN which is a known tumor suppressor that negatively regulates the PI3K/ AKT/mTOR pathway [21, 28] was elevated following EGFRmAbAuNPs+NIR treatment. Taken together, these data indicated that the PI3K/AKT/mTOR pathway is downregulated following EGFRmAbAuNPs+NIR treatment.
DNA damage is a frequent cause of apoptosis [29] . In this study, we further examined the expression levels of DNA damage response proteins. It has been reported that ATM, ATR, and BRCA1 stimulate both the DNA damage response and apoptosis [22] . The proteins CHK1 and CHK2 are cell cycle regulators and can be activated by ATM [30] [31] [32] . Unconjugated AuNPs were able to induce cell apoptosis, presumably because they increase oxidative stress and can also potentially bind to the major groove of DNA. In the presence of NIR radiation, both of these effects of AuNPs will disrupt genome integrity and cause apoptosis. We show here that a significant amount of our EGFRmAb conjugated AuNPs can enter the nucleus. Moreover, the expression levels of double strand DNA break repair factors, including ATM and BRCA1 were increased following EGFRmAb-AuNPs+NIR treatment, indicating the presence of DNA damage. These findings suggested that the AuNPs can potentially disrupt genome integrity and induce apoptosis.
In summary, we have demonstrated that conjugation with an EGFRmAb improved the selectivity and efficacy of AuNPs in FaDu cells. EGFRmAb-AuNPs+NIR treatment induced FaDu cell apoptosis via the PI3K/AKT/mTOR and DNA damage response pathways. This EGFRmAb-AuNPs+NIR-induced apoptosis could be a cooperative effect between EGFRmAb and AuNPs. PPTT with EGFRmAb-AuNPs+NIR could therefore be a new promising treatment for HC.
